Boston Scientific Net Change in Intangible Assets 2010-2025 | BSX
Boston Scientific annual/quarterly net change in intangible assets history and growth rate from 2010 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
- Boston Scientific net change in intangible assets for the quarter ending June 30, 2025 was $0M, a 0% increase year-over-year.
- Boston Scientific net change in intangible assets for the twelve months ending June 30, 2025 was $0M, a 0% increase year-over-year.
- Boston Scientific annual net change in intangible assets for 2024 was $0B, a 0% decline from 2023.
- Boston Scientific annual net change in intangible assets for 2023 was $0B, a 0% decline from 2022.
- Boston Scientific annual net change in intangible assets for 2022 was $0B, a 0% decline from 2021.
| Boston Scientific Annual Net Change in Intangible Assets (Millions of US $) |
|
|---|---|
| 2024 | $N/A |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $N/A |
| 2020 | $N/A |
| 2019 | $N/A |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| 2010 | $N/A |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $157.318B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $230.767B | 27.06 |
| Stryker (SYK) | United States | $150.713B | 30.68 |
| EssilorLuxottica (ESLOY) | France | $147.808B | 0.00 |
| Medtronic (MDT) | Ireland | $118.836B | 16.76 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.610B | 0.00 |
| Haleon (HLN) | United Kingdom | $44.040B | 25.18 |
| ResMed (RMD) | United States | $43.006B | 30.76 |
| Agilent Technologies (A) | United States | $34.551B | 22.52 |
| GE HealthCare Technologies (GEHC) | United States | $34.343B | 16.14 |
| Terumo (TRUMY) | Japan | $27.701B | 32.83 |
| Koninklijke Philips (PHG) | Netherlands | $27.289B | 18.05 |
| Insulet (PODD) | United States | $23.284B | 78.01 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.337B | 13.58 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.420B | 0.00 |
| Baxter (BAX) | United States | $12.604B | 9.74 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.222B | 30.20 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $3.958B | 10.70 |
| Envista Holdings (NVST) | United States | $3.609B | 25.26 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.369B | 8.42 |
| Prestige Consumer Healthcare (PBH) | United States | $3.283B | 14.57 |
| ICU Medical (ICUI) | United States | $3.164B | 21.54 |
| Haemonetics (HAE) | United States | $2.716B | 12.12 |
| LeMaitre Vascular (LMAT) | United States | $2.271B | 48.70 |
| Acuren (TIC) | United States | $2.108B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.894B | 11.92 |
| Curaleaf Holdings (CURLF) | Canada | $1.891B | 0.00 |
| AtriCure (ATRC) | United States | $1.872B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.757B | 75.46 |
| Phibro Animal Health (PAHC) | United States | $1.316B | 16.82 |
| AdaptHealth (AHCO) | United States | $1.300B | 18.48 |
| Tilray Brands (TLRY) | Canada | $1.266B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.241B | 2591.00 |
| Neogen (NEOG) | United States | $1.225B | 19.45 |
| Valneva SE (VALN) | France | $0.990B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.954B | 0.00 |
| InMode (INMD) | Israel | $0.936B | 8.66 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.626B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.607B | 0.00 |
| SNDL (SNDL) | Canada | $0.591B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.561B | 0.00 |
| ZimVie (ZIMV) | United States | $0.534B | 20.60 |
| Surmodics (SRDX) | United States | $0.532B | 0.00 |
| Evolus (EOLS) | United States | $0.497B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.482B | 16.60 |
| CeriBell (CBLL) | United States | $0.442B | 0.00 |
| Owens & Minor (OMI) | United States | $0.390B | 3.46 |
| Sanuwave Health (SNWV) | United States | $0.386B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.325B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.306B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.305B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.302B | 0.00 |
| Omeros (OMER) | United States | $0.299B | 0.00 |
| High Tide (HITI) | Canada | $0.290B | 0.00 |
| Brainsway (BWAY) | Israel | $0.287B | 58.46 |
| Viemed Healthcare (VMD) | United States | $0.284B | 21.50 |
| Aurora Cannabis (ACB) | Canada | $0.282B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.252B | 0.00 |
| Cerus (CERS) | United States | $0.243B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.241B | 0.00 |
| Quanterix (QTRX) | United States | $0.224B | 0.00 |
| Exagen (XGN) | United States | $0.222B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.219B | 0.00 |
| Organigram Global (OGI) | Canada | $0.214B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.195B | 16.30 |
| FitLife Brands (FTLF) | United States | $0.160B | 0.00 |
| Biote (BTMD) | United States | $0.159B | 5.28 |
| Jushi Holdings (JUSHF) | United States | $0.133B | 0.00 |
| Jin Medical (ZJYL) | China | $0.113B | 0.00 |
| MacroGenics (MGNX) | United States | $0.107B | 0.00 |
| Fonar (FONR) | United States | $0.095B | 12.19 |
| Quipt Home Medical (QIPT) | United States | $0.093B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Apyx Medical (APYX) | United States | $0.079B | 0.00 |
| Safety Shot (SHOT) | United States | $0.070B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 32.07 |
| Veru (VERU) | United States | $0.053B | 0.00 |
| Zynex (ZYXI) | United States | $0.050B | 0.00 |
| Nephros (NEPH) | United States | $0.044B | 34.83 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 14.95 |
| Trinity Biotech (TRIB) | Ireland | $0.028B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.012B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Sharps Technology (STSS) | United States | $0.008B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |